Cargando…

Will chemoradiation-based bladder-sparing therapy become a standard of care for muscle-invasive bladder cancer?

Detalles Bibliográficos
Autor principal:	Koga, Fumitaka
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2020
Materias:	Editorial Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7354303/ https://www.ncbi.nlm.nih.gov/pubmed/32676378 http://dx.doi.org/10.21037/tau-20-837

Ejemplares similares

Biomarkers for Predicting Clinical Outcomes of Chemoradiation-Based Bladder Preservation Therapy for Muscle-Invasive Bladder Cancer
por: Koga, Fumitaka, et al.
Publicado: (2018)

Impact of sarcopenia in bladder preservation therapy for muscle-invasive bladder cancer patients: a narrative review
por: Fukushima, Hiroshi, et al.
Publicado: (2022)

Bladder Sparing Approaches for Muscle-Invasive Bladder Cancers
por: El-Taji, Omar M. S., et al.
Publicado: (2016)

Bladder-sparing protocols in the treatment of muscle-invasive bladder cancer
por: Tholomier, Côme, et al.
Publicado: (2020)

Bladder preservation by neoadjuvant chemotherapy followed by concurrent chemoradiation for muscle-invasive bladder cancer
por: Elsayed, Dalia Hamouda, et al.
Publicado: (2023)

AB007. Bladder-sparing treatments for muscle-invasive bladder cancer
por: Li, Shengwen, et al.
Publicado: (2017)

ErbB2 and NFκB Overexpression as Predictors of Chemoradiation Resistance and Putative Targets to Overcome Resistance in Muscle-Invasive Bladder Cancer
por: Koga, Fumitaka, et al.
Publicado: (2011)

Organ-Sparing Strategies in Muscle-Invasive Bladder Cancer
por: Witjes, J Alfred, et al.
Publicado: (2021)

Treatment Discontinuation in Patients With Muscle-Invasive Bladder Cancer Undergoing Chemoradiation
por: Kotha, Nikhil V., et al.
Publicado: (2021)

Tumor downstaging in muscle invasive bladder cancer with neoadjuvant systemic therapy—does it lead to prolonged survival?
por: Tachibana, Isamu, et al.
Publicado: (2020)

Outcomes by time to definitive chemoradiation treatment for patients with muscle-invasive bladder cancer
por: Kotha, Nikhil V., et al.
Publicado: (2022)

Clinical benefit to regionalization of care for muscle invasive bladder cancer
por: Haque, Waqar, et al.
Publicado: (2018)

Trimodality Therapy in which Concurrent Chemoradiation with Concomitant Boost in Muscle Invasive TCC Urinary Bladder Cancer
por: Mohammed, Ayatallah Ali Youssief, et al.
Publicado: (2023)

Deceptive Muscle Invasive Bladder Cancer Recurrence With Benign Biopsy Foci After Bladder Sparing Treatment
por: Xu, Chuanliang, et al.
Publicado: (2015)

Systemic Therapy for Invasive Bladder Cancer: The Value Proposition
por: Raghavan, Derek
Publicado: (2016)

Editorial comment: the effect of neoadjuvant chemotherapy on tumour downstaging and outcomes in patients with muscle invasive bladder cancers
por: Ismaili, Nabil
Publicado: (2020)

Combined Modality Bladder-Sparing Therapy for Muscle-Invasive Bladder Cancer: How (Should) We Do It? A Narrative Review
por: Lemiński, Artur, et al.
Publicado: (2023)

Editorial comment: bladder preservation as a treatment strategy in muscle-invasive bladder cancer
por: Ajib, Khaled, et al.
Publicado: (2018)

Bladder-sparing approaches for muscle invasive bladder cancer: a narrative review of current evidence and future perspectives
por: Fan, Xinxiang, et al.
Publicado: (2023)

Comparison of sequential versus concurrent chemoradiation regimens in non-metastatic muscle-invasive bladder cancer
por: Vieira, Heidi M., et al.
Publicado: (2023)

Incidence and outcome of salvage cystectomy after bladder sparing therapy for muscle invasive bladder cancer: a systematic review and meta-analysis
por: Schuettfort, Victor M., et al.
Publicado: (2020)

Bladder Preservation with Neoadjuvant Chemotherapy Followed by Concurrent Chemoradiation for the Treatment of Muscle-invasive Carcinoma of the Bladder: A Single-Center Experience
por: Agrawal, Chinmayee, et al.
Publicado: (2020)

Tumor Markers as Predictors of Acute Kidney Injury Incidence and Staging of the Muscle-Invasive Bladder Cancer Receiving Chemoradiation Therapy
por: Warli, Syah Mirsya, et al.
Publicado: (2023)

Allelic imbalance at 1p36 may predict prognosis of chemoradiation therapy for bladder preservation in patients with invasive bladder cancer
por: Matsumoto, H, et al.
Publicado: (2004)

Preservation of Erectile and Ejaculatory Functions After Tetramodal Bladder-Sparing Therapy Incorporating Consolidative Partial Cystectomy Against Muscle Invasive Bladder Cancer
por: Uchida, Yusuke, et al.
Publicado: (2023)

Conservative Treatment of Gall Bladder Perforation is Not the Standard
por: Gerdes, Berthold, et al.
Publicado: (2014)

Neoadjuvant Chemotherapy–Guided Bladder-Sparing Treatment for Muscle-Invasive Bladder Cancer: Results of a Pilot Phase II Study
por: Shi, Hongzhe, et al.
Publicado: (2021)

Ultrasound-Mediated Gemcitabine Delivery Reduces the Normal-Tissue Toxicity of Chemoradiation Therapy in a Muscle-Invasive Bladder Cancer Model
por: Ruan, Jia-Ling, et al.
Publicado: (2021)

Patterns of Bladder Preservation Therapy Utilization for Muscle-Invasive Bladder Cancer
por: Rose, Tracy L., et al.
Publicado: (2016)

Bladder Preservation for Muscle Invasive Bladder Cancer
por: Mirza, Arafat, et al.
Publicado: (2016)

Induction therapy with ipilimumab and nivolumab followed by consolidative chemoradiation as organ-sparing treatment in urothelial bladder cancer: study protocol of the INDIBLADE trial
por: Stockem, C.F., et al.
Publicado: (2023)

Elevated Baseline Neutrophil Count Correlates with Worse Outcomes in Patients with Muscle-Invasive Bladder Cancer Treated with Chemoradiation
por: Meunier, Sébastien, et al.
Publicado: (2023)

Urodynamic study of bladder function following nerve sparing radical hysterectomy
por: Maneschi, Francesco
Publicado: (2014)

Simple and Efficient Stratification of Invasive Bladder Cancer Patients
por: Zoidakis, Jerome
Publicado: (2016)

Perioperative therapy in muscle invasive bladder cancer
por: Chatterjee, Ambarish, et al.
Publicado: (2021)

Massively parallel sequencing of urinary DNA—the dawn of non-invasive bladder cancer detection and surveillance?
por: Ward, Douglas G., et al.
Publicado: (2019)

Prediction of progression to muscle-invasive disease in patients with high-risk bladder cancer
por: Oszczudlowski, Maciej, et al.
Publicado: (2018)

Targeting splicing factors as molecular non-muscle invasive bladder cancer predictors
por: Lee, Kyoung-Hwa, et al.
Publicado: (2018)

Bladder-sparing Treatment in Patients with Bacillus Calmette-Guerin–unresponsive Non–muscle-invasive Bladder Cancer: An Analysis of Long-term Survival Outcomes
por: Tan, Wei Shen, et al.
Publicado: (2023)

Editorial Comment: Endoclips as novel fiducial markers in trimodality bladder preserving therapy of muscle-invasive bladder carcinoma: feasibility and patient outcomes
por: dos Reis, Rodolfo Borges, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_gqo6l5tjk4sv8seku9ds6b10lo